Advanced or Metastatic Solid Tumors, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Melanoma, Nasopharyngeal Carcinoma, Non-small Cell Lung Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Small Cell Lung Carcinoma, Squamous Cell Anal Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Triple Negative Breast Cancer, Urothelial Carcinoma
Conditions
Keywords
DUET-4, Advanced solid tumors, Metastatic solid tumors, Melanoma, Cervical Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, Hepatocellular/Liver Cancer, Urothelial Cancer, Renal Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Lymphocyte-activation gene 3 (LAG3), Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), Prostate Cancer, Nasopharyngeal carcinoma, Epithelial ovarian cancer, Fallopian tube cancer, Primary peritoneal carcinoma, Intrahepatic cholangiocarcinoma, Squamous Cell Anal Carcinoma, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Brief summary
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
Interventions
BIOLOGICALXmAb®22841
Monoclonal bispecific antibody
BIOLOGICALPembrolizumab (Keytruda®)
FDA-approved humanized monoclonal antibody
Sponsors
ICON Clinical Research
Xencor, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
PART A (Dose Escalation Cohorts) 1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 2. All subjects must have adequate archival tumor, or give consent to a fresh tumor biopsy. 3. Subjects have an ECOG performance status of 0-1. 4. Subjects in monotherapy and combination therapy cohorts must have histologically or cytologically confirmed advanced or metastatic solid tumors, including the following: 1. Melanoma 2. Cervical carcinoma 3. Pancreatic carcinoma 4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (TNBC) 5. Hepatocellular carcinoma 6. Urothelial carcinoma 7. Squamous cell carcinoma of the head and neck (HNSCC) 8. Nasopharyngeal carcinoma (NPC) 9. Renal cell carcinoma 10. Colorectal carcinoma or endometrial carcinoma 11. Small cell lung carcinoma or NSCLC 12. Gastric or gastroesophageal junction adenocarcinoma 13. Prostate adenocarcinoma 14. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 15. Intrahepatic cholangiocarcinoma 5. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab may have an advanced solid tumor that either: * has progressed after treatment with all available therapies that are known to confer clinical benefit, or is intolerant or has refused standard treatment (as for the XmAb22841 monotherapy cohorts), or * is of a tumor type for which pembrolizumab is an approved indication and has not previously been treated with an agent targeting PD1 or PDL1. PART B (Dose Expansion Cohorts) XmAb22841 Single Agent Cohort 1\. Must have histologically or cytologically confirmed advanced or metastatic solid tumor that has progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Eligible tumor types include the following: 1. Anti-PD1 refractory melanoma (or any uveal melanoma) 2. Anti-PD1 refractory NSCLC 3. Anti-PD1 refractory renal cell carcinoma (with clear cell component) 4. Anti-PD1 refractory urothelial carcinoma 5. Head and neck squamous cell carcinoma 6. Hepatocellular carcinoma 7. Gastric adenocarcinoma 8. Cervical carcinoma 9. Breast carcinoma that is estrogen receptor, progesterone receptor, and HER2 negative (TNBC) 10. Epithelial ovarian cancer 11. Nasopharyngeal carcinoma 12. Squamous cell anal carcinoma 13. Squamous cell penile carcinoma 14. Squamous cell vulvar carcinoma XmAb22841 + Pembrolizumab Cohorts 1. Anti-PD-1 refractory melanoma (excluding uveal melanoma) 2. Anti-PD-1 naïve melanoma (excluding uveal melanoma) 3. Anti-PD-1 refractory NSCLC 4. Anti-PD1 naïve NSCLC a. Must be PD-L1 high (TPS ≥ 50%), with no EGFR or ALK aberrations 5. Anti-PD1 naïve urothelial carcinoma 1. Must be PDL1 positive (CPS of ≥ 10), or ineligible for any platinum-containing chemotherapy regardless of PDL1 status; or 2. Had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Exclusion criteria
1. Prior treatment with an investigational anti-LAG3 therapy. 2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, 4P and 4Pi; and within 3 weeks for Cohorts 6M, 7Mi, 7M, 5P, and 6P. 3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the first dose of study treatment; or radiotherapy within 2 weeks of the first dose of study treatment; or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment. 4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX 40, CD137) AND were permanently discontinued from that treatment due to an irAE. 5. Failure to recover from any irAE from prior cancer therapy to Grade ≤ 1. 6. Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to Grade ≤ 2. 7. Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs). 8. Receipt of an organ allograft. 9. Treatment with antibiotics within 14 days prior to first dose of study drug. 10. Participants with known HIV. 11. Participants with known chronic hepatitis B virus (HBV) infection treated for less than 3 months prior to study enrollment and/or with a detectable HBV viral load; or hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to study enrollment and/or with a detectable HCV viral load; or active HBV/HCV coinfection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | 56 Days | Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs. |
Countries
United States
Outcome results
None listed